Survivorship beyond convalescence: 48-month quality-of-life outcomes after treatment for localized prostate cancer

Journal of the National Cancer Institute

Volumn 101, Issue 12, 2009, Pages 888-892

  Gore, John L ^a,b,c   Kwan, Lorna ^b   Lee, Steve P ^b   Reiter, Robert E ^b   Litwin, Mark S ^b  

^a VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BRACHYTHERAPY; CANCER LOCALIZATION; CANCER SURVIVOR; CLINICAL FEATURE; CONTROLLED STUDY; CONVALESCENCE; ENTEROPATHY; EXTERNAL BEAM RADIOTHERAPY; FEMALE SEXUAL DYSFUNCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MICTURITION DISORDER; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; STORAGE DISEASE; TREATMENT OUTCOME; URINE INCONTINENCE; AGED; CANCER STAGING; COMORBIDITY; COMPARATIVE STUDY; EDUCATIONAL STATUS; EPIDEMIOLOGY; ERECTILE DYSFUNCTION; HEALTH STATUS; METHODOLOGY; MIDDLE AGED; MORTALITY; PATHOLOGY; PROSTATE TUMOR; QUESTIONNAIRE; RADIATION INJURY; RADIOTHERAPY; SURVIVAL;

AGED; BRACHYTHERAPY; COMORBIDITY; CONFOUNDING FACTORS (EPIDEMIOLOGY); EDUCATIONAL STATUS; ERECTILE DYSFUNCTION; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATECTOMY; PROSTATIC NEOPLASMS; QUALITY OF LIFE; QUESTIONNAIRES; RADIATION INJURIES; RADIOTHERAPY; SURVIVAL ANALYSIS; TREATMENT OUTCOME; URINARY INCONTINENCE;

EID: 67449110637     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djp114     Document Type: Article

References (20)

1. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical pros-tatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998; 280 (11): 969-974.
2. Litwin MS, Gore JL, Kwan L, et al. Quality of life after surgery, external beam irradiation, or brachytherapy for early-stage prostate cancer. Cancer. 2007; 109 (11): 2239-2247.
3. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008; 358 (12): 1250-1261.
4. Ware JE Jr. SF-36 Health Survey: Manual and Interpretation Guide. New England Medical Center; Boston, MA: The Health Institute; 1993.
5. Litwin MS, Hays RD, Fink A, Ganz PA, Leake B, Brook RH. The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure. Med Care. 1998; 36 (7): 1002-1012.
6. Barry MJ, Fowler FJ Jr, O'Leary MP, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol. 1992; 148 (5): 1549-1557; discussion 1564.
7. Pinheiro JC, Bates DM. Approximations to the log-likelihood function in the nonlinear mixed-effects model. J Comput Graph Stat. 1995; 4 (1): 12-35.
8. Brandeis JM, Litwin MS, Burnison CM, Reiter RE. Quality of life outcomes after brachytherapy for early stage prostate cancer. J Urol. 2000; 163 (3): 851-857.
9. Litwin MS, Pasta DJ, Yu J, Stoddard ML, Flanders SC. Urinary function and bother after radical prostatectomy or radiation for prostate cancer: a longitudinal, multivariate quality of life analysis from the Cancer of the Prostate Strategic Urologic Research Endeavor. J Urol. 2000; 164 (6): 1973-1977.
10. Potosky AL, Davis WW, Hoffman RM, et al. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst. 2004; 96 (18): 1358-1367.
11. Talcott JA, Rieker P, Clark JA, et al. Patient-reported symptoms after primary therapy for early prostate cancer: results of a prospective cohort study. J Clin Oncol. 1998; 16 (1): 275-283.
12. Wei JT, Dunn RL, Sandler HM, et al. Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. J Clin Oncol. 2002; 20 (2): 557-566.
13. Cesaretti JA, Stone NN, Stock RG. Urinary symptom flare following I-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2003; 56 (4): 1085-1092.
14. Mantz CA, Nautiyal J, Awan A, et al. Potency preservation following conformal radiotherapy for localized prostate cancer: impact of neoadjuvant and rogen blockade, treatment technique, and patient-related factors. Cancer J Sci Am. 1999; 5 (4): 230-236.
15. Zelefsky MJ, Cowen D, Fuks Z, et al. Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma. Cancer. 1999; 85 (11): 2460-2468.
16. Litwin MS, Sadetsky N, Pasta DJ, Lubeck DP. Bowel function and bother after treatment for early stage prostate cancer: a longitudinal quality of life analysis from CaPSURE. J Urol. 2004; 172 (2): 515-519.
17. Hollenbeck BK, Dunn RL, Wei JT, McLaughlin PW, Han M, Sanda MG. Neoadjuvant hormonal therapy and older age are associated with adverse sexual health-related quality-of-life outcome after prostate brachytherapy. Urology. 2002; 59 (4): 480-484.
18. Hollenbeck BK, Wei JT, Sanda MG, Dunn RL, Sandler HM. Neoadjuvant hormonal therapy impairs sexual outcome among younger men who undergo external beam radiotherapy for localized prostate cancer. Urology. 2004; 63 (5): 946-950.
19. Speight JL, Elkin EP, Pasta DJ, et al. Longitudinal assessment of changes in sexual function and bother in patients treated with external beam radiotherapy or brachytherapy, with and without neoadjuvant androgen ablation: data from CaPSURE. Int J Radiat Oncol Biol Phys. 2004; 60 (4): 1066-1075.
20. Miller DC, Sanda MG, Dunn RL, et al. Long-term outcomes among localized prostate cancer survivors: health-related quality-of-life changes after radical prostatectomy, external radiation, and brachytherapy. J Clin Oncol. 2005; 23 (12): 2772-2780.